Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis

BACKGROUND: Baricitinib is a janus kinase (JAK1/JAK2) inhibitor developed for the treatment of patients suffering from rheumatoid arthritis (RA). Treating RA to the target of remission is current common practice. Cost-effectiveness of different treat-to-target (T2T) strategies, especially ones inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Van De Laar, Celine J, Oude Voshaar, Martijn A H, Fakhouri, Walid K H, Zaremba-Pechmann, Liliana, De Leonardis, Francesco, De La Torre, Inmaculada, Van De Laar, Mart A F J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167259/
https://www.ncbi.nlm.nih.gov/pubmed/32346301
http://dx.doi.org/10.2147/CEOR.S231558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167259/
https://www.ncbi.nlm.nih.gov/pubmed/32346301
http://dx.doi.org/10.2147/CEOR.S231558

Ejemplares similares